Recent studies reported that dual-binding AChE inhibitors targeting both CAS and PAS might not only attenuate memory impairments in AD patients by increasing ACh levels, but also provide additional benefit through delaying amyloid plaque accumulation [15,24,25,26]. Here, ACHE is linked to Alzheimer disease.